header image

Short-Course Regimen for MDR-TB

Trébucq A, Decroo T, Van Deun A et al.

4 Feb 2020

Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence

Molecular MDR diagnosis

Nguyen TNA, Anton-Le Berre V, Bañuls AL, Nguyen TVA.

8 May 2019

Molecular Diagnosis of Drug-Resistant Tuberculosis; A Literature Review

TB and its Treatment

Bansal R, Sharma D, Singh R.

16 Apr 2019

Tuberculosis and its Treatment: An Overview.

Controversies about MDR and XDR-TB treatment

Dheda K, Cox H, Esmail A, Wasserman S, Chang KC, Lange C.

16 Apr 2019

Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?

New treatment of TB

Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, et al.

16 Apr 2019

New drugs and perspectives for new anti-tuberculosis regimens.

TB in South Asia

Basnyat B, Caws M, Udwadia Z.

16 Apr 2019

Tuberculosis in South Asia: a tide in the affairs of men.

TB in older people

Yew WW, Yoshiyama T, Leung CC, Chan DP.

16 Apr 2019

Epidemiological, clinical and mechanistic perspectives of tuberculosis in older people.

Cost of TB in patients with HIV

de Siqueira-Filha NT, Legood R, Cavalcanti A, Santos AC.

16 Apr 2019

Cost of Tuberculosis Diagnosis and Treatment in Patients with HIV: A Systematic Literature Review.

RpoB mutations associated with Rifampicin-resistance in Mtb

Zaw MT, Emran NA, Lin Z.

16 Apr 2019

Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis.

TB elimination

Matteelli A, Rendon A, Tiberi S, Al-Abri S, et al.

16 Apr 2019

Tuberculosis elimination: where are we now?

Host Directed Therapies for Tuberculosis

Palucci I, Delogu G.

16 Apr 2019

Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.

Microbiome and TB

Namasivayam S, Sher A, Glickman MS, Wipperman MF.

16 Apr 2019

The Microbiome and Tuberculosis: Early Evidence for Cross Talk.

Drug discovery

du Plessis N, Kotze LA, Leukes V, Walzl G.

16 Apr 2019

Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.

Treatment of drug-resistant TB

Silva DR, Dalcolmo M, Tiberi S, Arbex MA, et al.

16 Apr 2019

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Consensus numbering for rpoB gene mutations

Andre E, Goeminne L, Cabibbe A, Beckert P, et al.

16 Apr 2019

Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria.

Management of patients with MDR and XDR-TB

Dheda K, Chang KC, Guglielmetti L, et al.

16 Apr 2019

Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.


Satta G, Atzeni A, McHugh TD.

16 Apr 2019

Mycobacterium tuberculosis and whole genome sequencing: a practical guide and online tools available for the clinical microbiologist.

MDR-TB and migration to Europe

argreaves S, Lönnroth K, Nellums LB, et al.

16 Apr 2019

Multidrug-resistant tuberculosis and migration to Europe.

Drug resistance testing

Schön T, Miotto P, Köser CU, Viveiros M, Böttger E, Cambau E

16 Apr 2019

Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives.

Targets for TB therapy

Nagaraja V, Godbole AA, Henderson SR, Maxwell A.

16 Apr 2019

DNA topoisomerase I and DNA gyrase as targets for TB therapy.


Kibret KT, Moges Y, Memiah P, Biadgilign S.

16 Apr 2019

Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies.

Line probe assays

Nathavitharana RR, Cudahy PG, Schumacher SG, et al.

16 Apr 2019

Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Risk of epidemic with MDR strains

McBryde ES, Meehan MT, Doan TN, et al.

16 Apr 2019

The risk of global epidemic replacement with drug-resistant Mycobacterium tuberculosis strains.

Isolation of Patients

Petersen E, Khamis F, Migliori GB, Bay JG, Marais B, et al.

14 Apr 2019

De-isolation of patients with pulmonary tuberculosis after start of treatment - clear, unequivocal guidelines are missing.

Delamanid and Bedaquiline

Migliori GB, Pontali E, Sotgiu G, Centis R, et al.

14 Apr 2019

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Isoniazid-resistant TB

Stagg HR, Lipman MC, McHugh TD, Jenkins HE.

14 Apr 2019

Isoniazid-resistant tuberculosis: a cause for concern?

Dormancy and Host Responses

Peddireddy V, Doddam SN, Ahmed N.

14 Apr 2019

Mycobacterial Dormancy Systems and Host Responses in Tuberculosis.

Combination Therapy for Tuberculosis

Kerantzas CA, Jacobs WR Jr.

14 Apr 2019

Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application.

Treatment of MDR TB

Bastos ML, Lan Z, Menzies D.

14 Apr 2019

An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.

MmpL transporters

Viljoen A, Dubois V, Girard-Misguich F, Blaise M, et al.

14 Apr 2019

The diverse family of MmpL transporters in mycobacteria: from regulation to antimicrobial developments.

Treatment of LTBI

Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, et al.

14 Apr 2019

Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.

Drug Discovery

Bald D, Villellas C, Lu P, Koul A.

14 Apr 2019

Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery.

Drug resistance

Nasiri MJ, Haeili M, Ghazi M, Goudarzi H et al.

14 Apr 2019

New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria.

Latent tuberculosis infection & TB elimination

LoBue PA, Mermin JH.

14 Apr 2019

Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA.

Drug discovery

Awasthi D, Freundlich JS.

14 Apr 2019

Antimycobacterial Metabolism: Illuminating Mycobacterium tuberculosis Biology and Drug Discovery.


Cadena AM, Fortune SM, Flynn JL.

13 Apr 2019

Heterogeneity in tuberculosis.


Naidoo A, Naidoo K, McIlleron H, Essack S, Padayatchi N.

13 Apr 2019

A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.


Lacobino A, Piccaro G, Giannoni F, Mustazzolu A, Fattorini L

13 Apr 2019

Fighting tuberculosis by drugs targeting nonreplicating Mycobacterium tuberculosis bacilli.

Child contact management

Szkwarko D, Hirsch-Moverman Y, Du Plessis L, Du Preez K, Car

13 Apr 2019

Child contact management in high tuberculosis burden countries: A mixed-methods systematic review.

Treatment of MDR TB in children

Mukherjee A, Lodha R, Kabra SK.

13 Apr 2019

Current therapies for the treatment of multidrug-resistant tuberculosis in children in India.

Prevention in HIV-infected children

Zunza M, Gray DM, Young T, Cotton M, Zar HJ.

13 Apr 2019

Isoniazid for preventing tuberculosis in HIV-infected children.

TB control

Pantoja T, Opiyo N, Lewin S, Paulsen E, Ciapponi A, Wiysonge

13 Apr 2019

Implementation strategies for health systems in low-income countries: an overview of systematic reviews.


13 Apr 2019

Mycobacteria-derived biomarkers for tuberculosis diagnosis. Druszczynska M, Wawrocki S, Szewczyk R, Rudnicka W.


13 Apr 2019

Tuberculous Meningitis in Children and Adults: New Insights for an Ancient Foe. Mezochow A, Thakur K, Vinnard C.

Diabetes and TB

Int J Infect Dis. 2017 Mar;56:45-53

9 Apr 2019

The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. Girardi E, Sañé Schepisi M, Goletti D, Bates M, Mwaba P, Yeboah-Manu D, Ntoumi F, Palmieri F, Maeurer M, Zumla A, Ippolito G.

HIV and TB

AIDS Res Ther. 2016 May 12;13:22

9 Apr 2019

Integrated therapy for HIV and tuberculosis. Manosuthi W, Wiboonchutikul S, Sungkanuparph S.

Immigrants population and TB treatment

Trans R Soc Trop Med Hyg. 2016 May;110(5):268-80

9 Apr 2019

Systematic review of risk factors for nonadherence to TB treatment in immigrant populations. Lin S, Melendez-Torres GJ.

Regimens for isoniazid-resistant tuberculosis

Thorax. 2016 Oct;71(10):940-9

9 Apr 2019

What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. Stagg HR, Harris RJ, Hatherell HA, Obach D, Zhao H, Tsuchiya N, Kranzer K, Nikolayevskyy V, Kim J, Lipman MC, Abubakar I.


Eur Respir J. 2016 Aug;48(2):516-25

9 Apr 2019

Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Albert H, Nathavitharana RR, Isaacs C, Pai M, Denkinger CM, Boehme CC.

Incarceration and TB transmission

Lancet. 2016 Sep 17;388(10050):1228-48

9 Apr 2019

The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman FS, El-Bassel N, Martin NK, Booth R, Stöver H, Dolan K, Vickerman P.


Clin Microbiol Rev. 2016 Oct;29(4):915-26

9 Apr 2019

Microbiome Changes during Tuberculosis and Antituberculous Therapy. Hong BY, Maulén NP, Adami AJ, Granados H, Balcells ME, Cervantes J.

Management of HIV-associated pulmonary tuberculosis

AIDS Res Ther. 2016 Sep 26;13:34

9 Apr 2019

Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. Gopalan N, Chandrasekaran P, Swaminathan S, Tripathy S.


Trends Mol Med. 2016 Dec;22(12):1060-1076

9 Apr 2019

Bacterial Pathogens versus Autophagy: Implications for Therapeutic Interventions. Kimmey JM, Stallings CL.

Translational Research for Tuberculosis Elimination

PLoS Med. 2016 Mar 2;13(3):e1001965

9 Apr 2019

Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions. Lienhardt C, Lönnroth K, Menzies D, Balasegaram M, Chakaya J, Cobelens F, Cohn J, Denkinger CM, Evans TG, Källenius G, Kaplan G, Kumar AM, Matthiessen L, Mgone CS, Mizrahi V, Mukadi YD, Nguyen VN, Nordström A, Sizemore CF, Spigelman M, Squire SB, Swaminathan S, Van Helden PD, Zumla A, Weyer K, Weil D, Raviglione M.

Next-Generation Whole Genome Sequencing

30 Jan 2019

Mycobacterium tuberculosis Next-Generation Whole Genome Sequencing: Opportunities and Challenges. Iketleng T, Lessells R, Dlamini MT, Mogashoa T, Mupfumi L, Moyo S, Gaseitsiwe S, de Oliveira T. Tuberc Res Treat. 2018 Dec 9;2018:1298542

Human genetics of mycobacterial disease.

4 Jan 2019

Human genetics of mycobacterial disease. Dallmann-Sauer M, Correa-Macedo W, Schurr E. Mamm Genome. 2018 Aug;29(7-8):523-538.

Alveolar Macrophages

4 Jan 2019

Alveolar Macrophages in the Resolution of Inflammation, Tissue Repair, and Tolerance to Infection. Allard B, Panariti A, Martin JG. Front Immunol. 2018 Jul 31;9:1777.

Tuberculosis in European Regions

4 Jan 2019

What Constitutes an Effective and Efficient Package of Services for the Prevention, Diagnosis, Treatment and Care of Tuberculosis among Refugees and Migrants in the WHO European Region? Themed Issues on Migration and Health, VIII [Internet]. Hargreaves S, Rustage K, Nellums LB, Powis J, Milburn J, Severoni S, Dara M, Puthoopparambil SJ, Friedland JS. Copenhagen: WHO Regional Office for Europe; 2018.

HIV and Tuberculosis

4 Jan 2019

High HIV and active tuberculosis prevalence and increased mortality risk in adults with symptoms of TB: a systematic review and meta-analyses. Nliwasa M, MacPherson P, Gupta-Wright A, Mwapasa M, Horton K, Odland JØ, Flach C, Corbett EL. J Int AIDS Soc. 2018 Jul;21(7):e25162.

BCG Complications

4 Jan 2019

Bacille Calmette-Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010-2017. Nunes-Santos CJ, Rosenzweig SD. Front Immunol. 2018 Jun 22;9:1423.

Molecular genetic tools

4 Jan 2019

Advances in the development of molecular genetic tools for Mycobacterium tuberculosis. Chhotaray C, Tan Y, Mugweru J, Islam MM, Adnan Hameed HM, Wang S, Lu Z, Wang C, Li X, Tan S, Liu J, Zhang T. J Genet Genomics. 2018 Jun 18. pii: S1673-8527(18)30114-0.


4 Jan 2019

Linezolid: a review of its properties, function, and use in critical care. Hashemian SMR, Farhadi T, Ganjparvar M. Drug Des Devel Ther. 2018 Jun 18;12:1759-1767.

Drug-resistant tuberculosis: diagnosis and treatment.

4 Jan 2019

Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Koch A, Cox H, Mizrahi V. Curr Opin Pharmacol. 2018 Jun 6;42:7-15.

Delamanid: From discovery to its use...

8 Sep 2018

Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis, Volume 111, 2018, pp. 20-30. Yongge Liu, Makoto Matsumoto, Hidekaza Ishida, Kinue Ohguro, Masuhiro Yoshitake, Rajesh Gupta, Lawrence Geiter, Jeffrey Hafkin.

Rapid molecular assays for detection of tuberculosis.

8 Sep 2018

Rapid molecular assays for detection of tuberculosis. Eddabra R, Ait Benhassou H. Pneumonia (Nathan). 2018 May 25;10:4.

Autophagy and Its Interaction...

8 Sep 2018

Autophagy and Its Interaction With Intracellular Bacterial Pathogens. Siqueira MDS, Ribeiro RM, Travassos LH. Front Immunol. 2018 May 23;9:935.

Mycobacterium tuberculosis: An Adaptable Pathogen...

8 Sep 2018

Mycobacterium tuberculosis: An Adaptable Pathogen Associated With Multiple Human Diseases. Chai Q, Zhang Y, Liu CH. Front Cell Infect Microbiol. 2018 May 15;8:158.

Molecular Targets Related Drug Resistance Mechanisms...

8 Sep 2018

Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains. Hameed HMA, Islam MM, Chhotaray C, Wang C, Liu Y, Tan Y, Li X, Tan S, Delorme V, Yew WW, Liu J, Zhang T. Front Cell Infect Microbiol. 2018 Apr 10;8:114.

New Players in Immunity to Tuberculosis...

8 Sep 2018

New Players in Immunity to Tuberculosis: The Host Microbiome, Lung Epithelium, and Innate Immune Cells. Gupta N, Kumar R, Agrawal B. Front Immunol. 2018 Apr 10;9:709.